Early Access
Peptides held to a higher standard
A new federal policy opens a path for licensed pharmacies to compound additional peptides. Olympia is preparing to expand our peptide line through our 503A pharmacy, with the same standards behind everything we make.
Early Access List
Be the First to Know
Availability updates, regulatory news, and first access to new prescriptions, sent directly from our pharmacy team.
What’s Changing
On October 28, 2026, HHS issued an interim policy allowing licensed 503A pharmacies to compound certain peptides under defined conditions while FDA completes its review. Each preparation must contain a single active ingredient and be prescribed for a specific patient. The policy is temporary and may change.
What we’re doing now
- Preparing our 503A pharmacy to meet every condition of the policy before compounding.
- Answering your clinical questions. Our PharmD team is available now. Contact us today.
- Sharing what we learn. Guides and articles in our Knowledge Center.
- Keeping you informed. Signing up on the Peptide Early Access list lets you hear about availability and regulatory changes first.